Overall, we believe that our findings are of interest 1) at translational level because our results suggest that the targeting of miR-4443/miR-4488 may be a therapeutic strategy to tackle the metastatic potential of MAPKi-resistant melanoma cells and 2) at a mechanistic level because we have identified nestin as a novel target of both oncomiRs. The gene discussed is NES; the disease is melanoma.